Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2025-08-29 Capital/Financing Update
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[정정제출요구]증권신고서(지분증권) (2025.11)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a capital increase (유상증자) and provides comprehensive risk factors (핵심투자위험) related to the company's business, financial status, and market position. This type of regulatory filing for capital raising is classified as a Capital/Financing Update.
2025-08-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including share pledges, collateral agreements, and disposals by major shareholders and special related parties. This falls under the 'Major Shareholding Notification' category.
2025-08-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Contract for Stock Collateral Provision involving a Change in the Largest Shareholder'. This type of filing is a standard regulatory disclosure in the Korean market (DART system) concerning capital structure and share pledging, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, Earnings, or Dividends.
2025-08-18 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Half-Year Report) for the company 'GemVax&KAEL Co., Ltd.' covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business descriptions, management discussions, and corporate governance details, which are characteristic of an interim financial report. It is not an announcement of a report (RPA) or a simple certification, as it contains substantive financial data and operational analysis. H1 2025
2025-08-14 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a previously filed 'Contract for Stock Collateral Provision Involving Change of Largest Shareholder'. It details specific changes to collateral amounts, contract dates, and creditor information. Since this is a formal regulatory disclosure of a financial transaction (collateralization) that does not fit into specific categories like M&A, Dividends, or Earnings, it falls under the fallback category for regulatory announcements.
2025-08-14 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a South Korean company (GemVax) regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares by the Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). This type of disclosure is a standard regulatory requirement for listed companies to report changes in collateralized shares held by major shareholders. Since it does not fit into specific categories like Annual Reports, Earnings Releases, or M&A, it falls under the 'Regulatory Filings' category.
2025-08-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.